Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial
- Written by PR Newswire
PXS-5505 shows good tolerability and >90% inhibition of target enzymes LOX and LOXL2 in myelofibrosis phase 1c dose escalation study
Safety committee approves progression to 6 month phase 2 study
SYDNEY, Oct. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data...
